Dynavax Technologies Corporation news

   Watch this stock
Showing stories 1 - 9 of about 9   

Articles published

DVAX 29.07 +1.97 (7.27%)
price chart
Analysts At William Blair Maintain Outperform On Dynavax Technologies
The firm points out that Dynavax has received the briefing book from the FDA by now and no news so far is good news. Moreover, Dynavax had communicated that if there were material information, the company would disclose it to the public. The firm ...
Dynavax Gets Crushed After Advisory Committee Vote
Assuming that the FDA decision turns out to be no (a favorable bet), we can still infer that Dynavax will conduct additional safety studies that can be included in Heplislav's next BLA.
Dynavax Falls After Vaccine Fails to Win Panel Backing  Bloomberg
Dynavax Upcoming Binary Event: HBV Vaccine Under Review By FDA Advisory Panel
Dynavax Technologies Corporation (NASDAQ:DVAX) is a small biotech company with an upcoming binary event on its stock. The FDA advisory committee will meet on November 15, 201,2 to discuss the company's HBV vaccine.
Dynavax's Heplisav Vaccine Works on Hepatitis B, FDA Says
Nov. 13 (Bloomberg) -- Dynavax Technologies Corp.'s Heplisav vaccine works against the contagious liver disease hepatitis B, Food and Drug Administration staff said.
Promising Biotech Stocks With Upcoming FDA Catalysts  Seeking Alpha
Stocks to Watch: Schiff Nutrition, Penn National Gaming, Gap
Shares rose 4.3% premarket to $34.70, as the company also raised its full-year earnings view. Shares of Dynavax Technologies Corp.DVAX +0.12% (DVAX) plunged 53% to $2.15 after a surprise FDA advisory-panel decision that could hold up approval of its ...
U.S. Stock Futures Retreat as Obama Holds Budget Talks
Dynavax Technologies Corp. tumbled 47 percent to $2.44 after its hepatitis B vaccine Heplisav failed to win the backing of U.S.
Dynavax to initiate phase I studies for TLR-9 agonist for asthma
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, will advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into phase I clinical studies.
JA Solar Has to Stoop to a Reverse Stock Split
What you are about to read is a sneaky way of announcing a reverse stock split to stay within the listing standards of the $1.00 share price rule.
The P/E Ratio, Health Care, and You
For example, a regulatory advisory panel's recent opinion on Dynavax's drug Heplisav ended up sinking the company's shares by 50% in one day -- all because the committee didn't feel Heplisav was safe enough for its standards. Official FDA approval ...